| Literature DB >> 32564756 |
Cinzia Severini1, Christian Barbato1, Maria Grazia Di Certo1, Francesca Gabanella1, Carla Petrella1, Arianna Di Stadio2, Marco de Vincentiis3, Antonella Polimeni3, Massimo Ralli2, Antonio Greco2.
Abstract
Alzheimer's disease (AD), recognized as the most common neurodegenerative disorder, is clinically characterized by the presence of extracellular beta-amyloid (Aβ) plaques and by intracellular neurofibrillary tau tangles, accompanied by glial activation and neuroinflammation. Increasing evidence suggests that self-misfolded proteins stimulate an immune response mediated by glial cells, inducing the release of inflammatory mediators and the recruitment of peripheral macrophages into the brain, which in turn aggravate AD pathology. The present review aims to update the current knowledge on the role of autoimmunity and neuroinflammation in the pathogenesis of the disease, indicating a new target for therapeutic intervention. We mainly focused on the NLRP3 microglial inflammasome as a critical factor in stimulating innate immune responses, thus sustaining chronic inflammation. Additionally, we discussed the involvement of the NLRP3 inflammasome in the gut-brain axis. Direct targeting of the NLRP3 inflammasome and the associated receptors could be a potential pharmacological strategy since its inhibition would selectively reduce AD neuroinflammation. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.Entities:
Keywords: Alzheimer's disease; autoimmunity; microbiota-gutinflammasome-zzm321990brain-axis; microglial NLRP3 inflammasome; neuroinflammation; therapeutic targets
Year: 2021 PMID: 32564756 DOI: 10.2174/1570159X18666200621204546
Source DB: PubMed Journal: Curr Neuropharmacol ISSN: 1570-159X Impact factor: 7.363